United-Guardian Inc. reports third quarter sales and net income decline
United-Guardian Inc. reported a decline in third quarter sales and net income for 2025. Net sales fell to $2.3 million from $3.1 million in 2024, while net income decreased to $268,400 ($0.06 per share) from $865,500 ($0.19 per share). For the first nine months, net sales were $7.6 million, down from $9.7 million, and net income dropped to $1.5 million ($0.32 per share) from $2.7 million ($0.60 per share). The company is working to expand its pharmaceutical products and has new marketing agreements for personal care items.
United-Guardian Inc. reported net sales of $2.3 million for the third quarter of 2025, down from $3.1 million in the same period of 2024. Net income for the quarter decreased to $268,400 ($0.06 per share) from $865,500 ($0.19 per share) last year. For the first nine months of 2025, net sales were $7.6 million, compared to $9.7 million in 2024, while net income fell to $1.5 million ($0.32 per share) from $2.7 million ($0.60 per share). Pharmaceutical and medical product sales increased by 10% and 6%, respectively, during the first nine months. The company is working with a pharmaceutical consultant to expand Renacidin’s presence on drug formularies and has entered into new marketing agreements for personal care products. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United-Guardian Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-007076), on November 06, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
